Related references
Note: Only part of the references are listed.mTOR inhibitors in cancer therapy
Yekaterina Y. Zaytseva et al.
CANCER LETTERS (2012)
Unexpected applications of secondary metabolites
Preeti Vaishnav et al.
BIOTECHNOLOGY ADVANCES (2011)
Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells
Maiko Suzuki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen
Yoko Hiwatashi et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Yesid Alvarado et al.
TARGETED ONCOLOGY (2011)
Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications
Soichiro Kanoh et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Azithromycin reduces the viability of human bronchial smooth muscle cells
Rodopi Stamatiou et al.
JOURNAL OF ANTIBIOTICS (2010)
Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
Ryan J. O. Dowling et al.
BIODRUGS (2009)
Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice
Wan C. Tsai et al.
INFLAMMATION RESEARCH (2009)
Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells
Uppoor G. Bhat et al.
PLOS ONE (2009)
Vincristine: Can Its Therapeutic Index Be Enhanced?
Andrew Moore et al.
PEDIATRIC BLOOD & CANCER (2009)
Anti-tumor activity of N-thiolated β-lactam antibiotics
Di Chen et al.
CANCER LETTERS (2008)
Antiproliferation and apoptosis induction of paeonol in HepG2 cells
Shu-Ping Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin
Richa Chandra et al.
CLINICAL PHARMACOKINETICS (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Antibiotic-induced apoptosis in human activated peripheral lymphocytes
JI Kadota et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats
E Asakura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Novel N-thiolated β-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells
A Kazi et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL
S Mizunoe et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2004)
Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells
MF Romano et al.
EUROPEAN JOURNAL OF CANCER (2004)
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
WH Mondesire et al.
CLINICAL CANCER RESEARCH (2004)
A novel β-lactam antibiotic activates tumor cell apoptotic program by inducing DNA damage
DM Smith et al.
MOLECULAR PHARMACOLOGY (2002)
Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin:: effects of Streptococcus pneumoniae
CC Koch et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
The newer macrolides: Azithromycin and clarithromycin
JM Zuckerman
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2000)
Share Paper
